Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Julià Panés"'
Autor:
Cristina Romero-Mascarell, Gloria Fernández-Esparrach, Cristina Rodríguez-De Miguel, Maria Carme Masamunt, Sonia Rodríguez, Jordi Rimola, Miguel Urpí, Gherzon Simon Casanova, Ingrid Ordás, Elena Ricart, Berta Caballol, Agnès Fernández-Clotet, Julià Panés, Josep Llach, Begoña González-Suárez
Publikováno v:
Diagnostics, Vol 12, Iss 9, p 2226 (2022)
(1) Background: Fecal calprotectin (FC) correlates well with colonic inflammatory activity of Crohn’s disease (CD); data about relation of FC and small bowel (SB) lesions are still contradictory. The main aim was to analyze the relationship between
Externí odkaz:
https://doaj.org/article/dd4777a967f04740a184e022666a59fe
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 106, Iss 1, Pp 65-66
Externí odkaz:
https://doaj.org/article/e42e1a89a51347618bc9b2cff9521b26
Autor:
Berta Caballol, Agnès Fernández-Clotet, Julià Panés, Maria Carme Masamunt, Marta Gallego, Rebeca Barastegui, Alejandro Vara, Àngel Giner, Elena Ricart, Ingrid Ordàs
Publikováno v:
Gastroenterología y Hepatología. 46:S111
Autor:
Leonardo Salese, R Cohen, Walter Reinisch, Julià Panés, Christina Ha, Bruce E. Sands, Nervin Lawendy, Rajiv Mundayat
Publikováno v:
Journal of Crohn's and Colitis. 15:S294-S296
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present an updated analysis of non-melanoma skin cancer (NMSC) events in the tofacitinib UC clinical programme, including final data from
Autor:
Julià Panés, S B Connelly, Rajiv Mundayat, Nancy Sunna, Gerhard Rogler, Nervin Lawendy, Ala I. Sharara, Ryan C. Ungaro, Matthew A. Ciorba
Publikováno v:
Journal of Crohn's and Colitis. 15:S357-S359
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present an updated analysis of adjudicated malignancies in the tofacitinib UC clinical programme, including final data from the open-labe
Autor:
Axel Dignass, Daniel R. Gaya, M Nazar, L Peyrin-Biroulet, Marco Daperno, Alessandro Armuzzi, Mark Löwenberg, G R D’Haens, Lioudmila Ni, Julià Panés, Fernando Magro, Sheldon Sloan, M Le Bars, Milan Lukas, M Lahaye, Silvio Danese, Severine Vermeire
Publikováno v:
Journal of Crohn's and Colitis. 14:S049-S052
Background Treat-to-target (T2T) strategy may optimise IBD disease management. We describe interim clinical and endoscopic results of the STARDUST trial in Crohn’s disease (CD) patients, following 16 weeks (W) of ustekinumab (UST) induction. Method
Autor:
Isabel Quintanilla, Gerhard Jung, Mireya Jimeno, Juan José Lozano, Julia Sidorova, Jordi Camps, Sabela Carballal, Luis Bujanda, Maria Isabel Vera, Enrique Quintero, Marta Carrillo-Palau, Miriam Cuatrecasas, Antoni Castells, Julià Panés, Elena Ricart, Leticia Moreira, Francesc Balaguer, Maria Pellisé
Publikováno v:
Addi. Archivo Digital para la Docencia y la Investigación
instname
instname
INTRODUCTION: Colorectal cancer (CRC) is a potentially life-threatening complication of long-standing ulcerative colitis (UC). MicroRNAs (miRNA) are epigenetic regulators that have been involved in the development of UC-associated CRC. However, their
Autor:
Agnès Fernández-Clotet, Miriam Escapa, Begoña González-Suárez, Julià Panés, Angels Ginès, Berta Carballol, Gloria Fernández-Esparrach, Ingrid Ordás, Elena Ricart, Antonio Giordano
Publikováno v:
43 Congreso de la Sociedad Española de Endoscopia Digestiva (Libro de Comunicaciones).
Autor:
M. Barreiro-de Acosta, E. Domènech, M Esteve, Y Zabana, A Gutiérrez, B. Beltrán, M. Chaparro, Pilar Nos, X. Calvet, Javier P. Gisbert, Julià Panés
Publikováno v:
Journal of Crohn's and Colitis. 14:S061-S063
Background Spanish inflammatory bowel disease (IBD) group (GETECCU) mission is to promote healthcare, teaching and research of excellence. Our vision is to establish standards of quality of care and generate a mark of excellence and reliability for I
Autor:
Walter Reinisch, Julià Panés, Silvio Danese, Bruce E. Sands, Chinyu Su, Nana Koram, Andrew John Thorpe, Daniel Quirk, Irene Modesto, Nervin Lawendy, Thomas V. Jones, W J Sandborn, Flavio Steinwurz, Kenneth Kwok
Publikováno v:
Journal of Crohn's and Colitis. 14:S498-S500
Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of UC. In data analysed from a large, ongoing (data cut-off February 2019 [a]; database unlocked; data may be subject to change), post-authorisation safety study in pat